Literature DB >> 12732395

Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis.

Branka Zegura1, Irena Keber, Miran Sebestjen, Wolfgang Koenig.   

Abstract

Estrogen replacement therapy (ERT) has been found to be associated with increased cardiovascular risk in the first year after initiation of ERT. We compared the effects of oral and transdermal estradiol (E2) replacement therapy on markers of inflammation, coagulation and fibrinolysis in a randomized double-blind trial. Forty-three healthy women were randomized 6 weeks after surgically induced menopause to receive treatment with either oral or transdermal E2 over a period of 28 weeks. At baseline and after 28 weeks, levels of serum lipids and lipoproteins, and markers of coagulation, fibrinolysis and inflammation were determined. Among fibrinolytic parameters, oral E2 shortened euglobulin clot lysis time (P<0.05) and reduced tissue type plasminogen activator antigen (P=0.01) and plasminogen activator inhibitor activity (P<0.05). Among coagulation parameters, both routes of E2 replacement decreased fibrinogen levels (P=0.002 for oral and P=0.007 for transdermal E2). Oral E2 resulted in an increase in C-reactive protein (CRP) from 2.15 (0.71-4.05) to 3.41 (1.12-5.92) mg/l (P=0.04), while transdermal E2 showed no effect. Levels of serum amyloid A (SAA), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) did not change significantly after oral and transdermal E2. Oral E2 significantly improved the lipid profile, while transdermal E2 had a less pronounced effect. Both oral and transdermal E2 significantly reduced fasting glucose. Oral E2 was associated with a pro-inflammatory response, but at the same time improved fibrinolytic capacity, showed no pro-coagulatory effects, and acted beneficially on lipids and lipoproteins. There was no influence of transdermal E2 on markers of coagulation activation, fibrinolysis and inflammation, but it decreased fibrinogen levels significantly. Further studies are needed to explore the clinical relevance of these observations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732395     DOI: 10.1016/s0021-9150(03)00088-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  11 in total

1.  Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women.

Authors:  Michael P Corcoran; Mohsen Meydani; Alice H Lichtenstein; Ernst J Schaefer; Alice Dillard; Stefania Lamon-Fava
Journal:  J Endocrinol       Date:  2010-05-18       Impact factor: 4.286

2.  Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.

Authors:  Victor W Henderson; Roberta Diaz Brinton
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

3.  Association of endogenous hormones with C-reactive protein, fibrinogen, and white blood count in post-menopausal women.

Authors:  Aaron R Folsom; Sherita Hill Golden; Lori L Boland; Moyses Szklo
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

4.  Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen.

Authors:  Marianne Canonico; Martine Alhenc-Gelas; Geneviève Plu-Bureau; Valérie Olié; Pierre-Yves Scarabin
Journal:  Menopause       Date:  2010 Nov-Dec       Impact factor: 2.953

5.  The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial.

Authors:  D E Bonds; N Lasser; L Qi; R Brzyski; B Caan; G Heiss; M C Limacher; J H Liu; E Mason; A Oberman; M J O'Sullivan; L S Phillips; R J Prineas; L Tinker
Journal:  Diabetologia       Date:  2006-01-27       Impact factor: 10.122

6.  Role of aging versus the loss of estrogens in the reduction in vascular function in female rats.

Authors:  James P Stice; Jason P Eiserich; A A Knowlton
Journal:  Endocrinology       Date:  2008-09-11       Impact factor: 4.736

Review 7.  Diet and C-reactive protein.

Authors:  Peter M Clifton
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

8.  High Sensitivity C - Reactive Protein is Associated with Diastolic Dysfunction in Young African Americans without Clinically Evident Cardiac Disease.

Authors:  Venkataraman Rajaram; Arthur T Evans; Gloria C Caldito; Russell F Kelly; Leon Fogelfeld; Henry R Black; Rami Doukky
Journal:  Open Cardiovasc Med J       Date:  2011-08-22

9.  The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial.

Authors:  M Lazzeroni; D Macis; A Decensi; S Gandini; M T Sandri; D Serrano; A Guerrieri-Gonzaga; H Johansson; S Mora; C Daldoss; U Omodei; B Bonanni
Journal:  Ecancermedicalscience       Date:  2008-02-06

10.  Is the WHI relevant to HRT started in the perimenopause?

Authors:  S Mitchell Harman; Eliot A Brinton; Thomas Clarkson; Christopher B Heward; Harvey S Hecht; Richard H Karas; Debra R Judelson; Frederick Naftolin
Journal:  Endocrine       Date:  2004-08       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.